Evidence map›Paper›PMID 29999442›Full record

ReviewExpert review of proteomics2018

Utilizing proteomics to understand and define hypertension: where are we and where do we go?

Christian Delles, Emma Carrick, Delyth Graham, Stuart A Nicklin

Open access · hybridAbstract readReview
In one paragraph

Review in Expert review of proteomics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Is there a role for proteomics in diabetic renal disease?Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2020
    Article
  7. Molecular Mechanisms of Kidney Injury and Repair in Arterial Hypertension.International journal of molecular sciences · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Christian Dellesa Institute of Cardiovascular and Medical Sciences , University of Glasgow , Glasgow , UK.ORCID 0000-0003-2238-2612
Emma Carricka Institute of Cardiovascular and Medical Sciences , University of Glasgow , Glasgow , UK.
Delyth Grahama Institute of Cardiovascular and Medical Sciences , University of Glasgow , Glasgow , UK.ORCID 0000-0002-7328-4708
Stuart A Nicklina Institute of Cardiovascular and Medical Sciences , University of Glasgow , Glasgow , UK.ORCID 0000-0002-9691-6210
University of Glasgow · GB

Funding

British Heart Foundation PG/17/17/32877British Heart Foundation RE/13/5/30177Medical Research Council MR/L019108/1
6 · The paper itself

Abstract

introductionHypertension is a complex and multifactorial cardiovascular disorder. With different mechanisms contributing to a different extent to an individual's blood pressure, the discovery of novel pathogenetic principles of hypertension is challenging. However, there is an urgent and unmet clinical need to improve prevention, detection, and therapy of hypertension in order to reduce the global burden associated with hypertension-related cardiovascular diseases. Areas covered: Proteomic techniques have been applied in reductionist experimental models including angiotensin II infusion models in rodents and the spontaneously hypertensive rat in order to unravel mechanisms involved in blood pressure control and end organ damage. In humans proteomic studies mainly focus on prediction and detection of organ damage, particularly of heart failure and renal disease. While there are only few proteomic studies specifically addressing human primary hypertension, there are more data available in hypertensive disorders in pregnancy, such as preeclampsia. We will review these studies and discuss implications of proteomics on precision medicine approaches. Expert commentary: Despite the potential of proteomic studies in hypertension there has been moderate progress in this area of research. Standardized large-scale studies are required in order to make best use of the potential that proteomics offers in hypertension and other cardiovascular diseases.

Indexed as

AnimalsDisease Models, AnimalHumansHypertensionPrecision MedicineProteomicshypertensionprecision medicineproteomics

Identifiers

PMID29999442
PMCPMC6092739
OpenAlexW2883280159

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.